
Opinion|Videos|January 27, 2025
Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care
Panelists discuss how faster-acting treatments like zuranolone might improve patient outcomes and quality of life, the initial signs to monitor for assessing effectiveness, barriers to accessing such therapies in underserved populations and strategies to increase accessibility, approaches to ensuring safety while addressing distress in patients with intrusive thoughts, effective strategies for managing sleep issues in postpartum depression (PPD), advice for the psychiatry community when treating PPD, and how to tailor advice for clinicians working with underserved populations.
Advertisement
Episodes in this series

Advertisement
Related to this article

Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.

Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.

Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.

Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.

Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.

The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.

Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Shelves Fast-Track Drug Review Initiative
2
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
3
Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1
4
Reviewing Roluperidone as Treatment for Negative Symptoms in Schizophrenia
5


